Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

NCT05090891 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05090891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05090891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2022
Completion date
January 20, 2033
Enrollment
98 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva (fop)